News for Healthier Living

Antibody-Drug Conjugate Achieves High Response Rates as Frontline Treatment in Aggressive, Rare Blood Cancer

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

February 11, 2026


February 11 2026

February 10 2026

February 9 2026

February 8 2026

February 7 2026

February 6 2026

February 5 2026

February 4 2026

February 3 2026

February 2 2026

February 1 2026

January 31 2026

January 30 2026

January 29 2026